COHERUS BIOSCIENCES INC (CHRS)
US19249H1032 - Common Stock
CHRS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. CHRS may be in some trouble as it scores bad on both profitability and health. CHRS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CHRS had negative earnings in the past year.
In the past year CHRS has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CHRS reported negative net income in multiple years.
In multiple years CHRS reported negative operating cash flow during the last 5 years.
1.2 Ratios
CHRS has a Return On Assets of -0.09%. This is amongst the best in the industry. CHRS outperforms 92.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-46.91%
ROA(5y)-20.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CHRS's Gross Margin of 44.71% is fine compared to the rest of the industry. CHRS outperforms 77.42% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
CHRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CHRS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CHRS has been increased compared to 5 years ago.
The debt/assets ratio for CHRS has been reduced compared to a year ago.
2.2 Solvency
CHRS has an Altman-Z score of -4.02. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
CHRS has a Altman-Z score (-4.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.02 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
CHRS has a Current Ratio of 1.25. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
CHRS has a Current ratio of 1.25. This is amonst the worse of the industry: CHRS underperforms 84.30% of its industry peers.
A Quick Ratio of 1.09 indicates that CHRS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.09, CHRS is not doing good in the industry: 85.01% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
CHRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.50%, which is quite impressive.
The Revenue has grown by 44.17% in the past year. This is a very strong growth!
The Revenue for CHRS have been decreasing by -18.53% on average. This is quite bad
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.3%
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5YN/A
Sales Q2Q%-5.09%
3.2 Future
CHRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.90% yearly.
CHRS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.88% yearly.
EPS Next Y71.09%
EPS Next 2Y39.14%
EPS Next 3Y23.67%
EPS Next 5Y19.9%
Revenue Next Year-2.31%
Revenue Next 2Y6.9%
Revenue Next 3Y9.67%
Revenue Next 5Y15.88%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CHRS's earnings are expected to grow with 23.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.14%
EPS Next 3Y23.67%
5. Dividend
5.1 Amount
No dividends for CHRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COHERUS BIOSCIENCES INC
NASDAQ:CHRS (12/4/2024, 1:36:08 PM)
1.82
+0.11 (+6.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap209.68M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.71% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y71.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y